Reframe Daily is where Christin Chong (neuroscience PhD, chaplain, healthtech strategy consultant) curates optimistic and credible healthtech news so you don’t have to.

Today in one sentence: An AI tool called GRAPE can now spot tiny stomach cancers on CT scans; a glue-like sleeve got FDA clearance to help surgeons fix cut nerves without stitches; the new lung-cancer drug Datroway earned full FDA approval; early tests show the pill zidesamtinib shrank stubborn ROS1 lung tumors; and the FDA hinted it may speed review of a heart cell therapy for Duchenne muscular dystrophy.

Estimated reading time saved: 10 hours 53 min. Check here for all past issues.

If you are passionate about making it easier for everyone to be healthy, schedule a chat with me and let’s collab!

Good news: Doctors built an AI system called GRAPE that finds tiny, early-stage stomach cancers on ordinary CT scans—so people can treat cancer when it’s easiest to cure.

AI-based large-scale screening of gastric cancer from non-contrast CT imaging

Market readiness: 😊😊 (validated in 18 hospitals, but still needs FDA clearance and hospital roll-out) 

Good news: Surgeons may soon fix cut nerves without delicate stitches. A biodegradable, glue-like sleeve just earned FDA clearance, promising quicker surgeries and straighter nerve regrowth.

Device that uses biodegradable polymers to repair peripheral nerves gets FDA clearance

Market readiness: 😊😊😊😊 (FDA-cleared; maker says first U.S. launch is only months away) 

Good news: A “guided-missile” drug, Datroway, won full U.S. approval to attack hard-to-treat EGFR-mutated lung cancers, giving patients a brand-new option after other drugs fail.

US approves AstraZeneca, Daiichi’s treatment for lung cancer

Market readiness: 😊😊😊😊😊 (fully FDA-approved and headed to pharmacies within weeks) 

Good news: Early trial data show the pill zidesamtinib shrank tumors in people whose ROS1-positive lung cancer had stopped responding to any other treatment—offering hope where few options exist.

Nuvalent says its ROS1-targeted drug shrank lung tumors after other drugs failed

Market readiness: 😊😊 (Phase 1/2 study; larger trials and full FDA review still ahead) 

Good news: The FDA signaled it may skip an outside advisory meeting for a cell therapy targeting heart problems in Duchenne muscular dystrophy—often a sign the review is on track and could speed patient access.

Capricor says FDA may not convene expert panel for its Duchenne cell therapy

Market readiness: 😊😊😊 (in final FDA review with a decision due August 31)